Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
LOS ANGELES, March 30, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq:RGLS) concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. When this information was released, the stock price of Regulus fell, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
